Acarix's CADScor Attracts Chinese Investment
Scandinavian device maker Acarix has gained Chinese investment to boost production of its CE-marked CADScorSystem ahead of a commercial launch in 2017. The company will also form a joint venture in China.
You may also be interested in...
The latest clinical data on Acarix's handheld acoustic device, the CADScor system, backs the use of the technology as a frontline test for ruling out coronary artery disease in patients presenting with suspicious chest pain. Results from a multi-center trial showed CADScor achieved a 97% negative predictive value.
This year’s AngloNordic Medtech conference saw a raft of new companies looking for funding. Clinica picks its highlights from the meeting, held in London on 23 April
Experts from the University of Chicago are advocating for helmet ventilation for COVID-19 patients. Medtech Insight spoke to acute nurse practitioner Aurika Savickaite who is helping lead an initiative to educate and raise awareness of the technology.